These observations suggest that FLRT2 methylation alterations can be exploited as predictive and diagnosis biomarkers for CRC metastasis and tumorigenesis, and also provide a therapeutic option for the disease. This evidence concerns the gene FLRT2 and colorectal carcinoma.